Corton Capital’s Acrivon Therapeutics ACRV Stock Holding History

Corton Capital’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,159	Closed	-$73.2K	–	165
2024 Q4	$73.2K	Buy	+12,159	New	+$88.4K	0.04%	359

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's ACRV Position: Q1 2025 in Review

Corton Capital sold out of Acrivon Therapeutics (ACRV) in Q1 2025, closing a stake of 12,159 shares — an estimated $73.2K sold.

Corton Capital first reported a position in ACRV in Q4 2024 and held it in 1 quarter. The position peaked at $73.2K in Q4 2024. 63 funds tracked by Wall St. Rank hold ACRV as of Q1 2025.

Corton Capital reported no remaining Acrivon Therapeutics position as of Q1 2025 after selling out during the quarter.
Corton Capital sold 12,159 Acrivon Therapeutics shares in Q1 2025, an estimated $73.2K.
Corton Capital first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 1 quarter.
Corton Capital's Acrivon Therapeutics position peaked at $73.2K in Q4 2024.
63 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.